Proud to be presenting our abstract 4716 An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL) at ASH 2019 between 6 and 8 PM tonight in Orlando.
ASH 2019: Proud to be presenting our abstract... - CLL Support
ASH 2019
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
5 Replies
•
Good work, Brian!
We are proud of you, too!
Our CLL specialist is at this conference as well.
Thanks for your dedication and hard work!!!
Thank you!!!!
Not what you're looking for?
You may also like...
ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
of the peripheral numbers of malignant lymphocytes.
Our findings suggest that the drug might...
ASH 2019: U-MRD by subgroup (ibrutinib+venetoclax) CAPTIVATE trial
Slide from the oral presentation of this abstract:...
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista
Centre discusses the maturing CLL clinical trial data presented at ASH 2019.
Phenomenal 3 and 4...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
Kipps at ASH 2018, he discusses resistance and how to possibly avoid it:...
Related Posts
- ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR
2022 ASH Conference Report: Should MPN Patients Follow the Mediterranean Diet?- Late breaking CLL abstract at ASH 2017 - VR vs BR
Diagnosed with CLL November 2019
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)
